Novo Nordisk's European Logistics Breakthrough Meets US Pricing Headwinds

EMA relaxes Wegovy cold-chain rules, cutting EU distribution costs. Novo faces 2026 sales decline from US pricing pressure and competition, with key CagriSema FDA decision due.

Novo Nordisk has secured a significant operational advantage in Europe, even as it braces for its first sales decline in 25 years. The European Medicines Agency (EMA) has approved new transport guidelines for the weight-loss drug Wegovy, relaxing the strict requirement for an unbroken cold chain. This move cuts distribution costs and simplifies the fast-growing market for direct-to-patient medication delivery.

The change is a logistical milestone. Previously, the injectable had to be refrigerated throughout its entire journey. Now, on the final leg from pharmacy to consumer, it can be stored for up to 48 hours at temperatures as high as 30 degrees Celsius. Wegovy is the first GLP-1 weight-loss drug in Europe to offer this flexibility, easing packaging burdens for mail-order pharmacies and offering patients more discreet and convenient home delivery.

This European progress stands in stark contrast to the mounting pressures across the Atlantic. The company is preparing for a currency-adjusted sales decline of 5% to 13% in 2026. The primary drivers are stricter US government pricing rules and reduced insurance coverage for obesity medications under Medicaid. Competition is also intensifying, with rival Eli Lilly now commanding over 60% of the US market for weight-loss injections. The upcoming quarterly report in May will provide the first clear look at margin performance under this new US pricing regime.

In response to a challenging market environment, Novo Nordisk's management is actively supporting its share price. Since early February, the company has repurchased nearly ten million of its own shares for approximately 2.59 billion Danish kroner. This is part of a larger 12-month buyback program totaling 15 billion kroner, with the company now holding 0.6% of its own share capital. The stock, trading around 32.12 euros, remains under significant pressure, down roughly 46% over the past twelve months and well below its 200-day moving average.

Amid these headwinds, the product pipeline is critical. In the US, the higher-dose Wegovy HD (7.2 mg) is now available nationwide, with clinical trials showing an average weight loss of about 21% over 72 weeks. The company is also advancing an oral semaglutide variant. However, the most anticipated near-term catalyst is CagriSema, a dual-drug combination. Phase 3 trial data showed an average weight reduction of 23%, and the US Food and Drug Administration (FDA) is currently reviewing the application. A regulatory decision is expected in October 2026.

The EMA's relaxed cold-chain rules provide a tangible structural benefit for Novo Nordisk's European distribution, coinciding with the US launch of Wegovy HD. Yet, the path forward is bifurcated: operational strengths are being solidified on one continent while fundamental financial pressures mount on another. All eyes are now on the May quarterly report to gauge the immediate impact of US pricing changes, setting the tone for the stock until the FDA's verdict on CagriSema arrives.